CIT eCapital, LLC – Trademark Portfolio
Entity Type: 16
CIT eCapital, LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SUPPLE. The owner is based in EAST HADDAM, CT.
50 BEEBE ROAD
EAST HADDAM, CT 06423
Showing of trademarks Trademarks
Trademark Classifications
CIT eCapital, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does CIT eCapital, LLC have?
CIT eCapital, LLC has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 abandoned.
What trademark classes does CIT eCapital, LLC file in?
CIT eCapital, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages), Class 29 (Meats & Processed Foods), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CIT eCapital, LLC's most well-known trademarks?
CIT eCapital, LLC's registered trademark portfolio includes well-known marks such as SUPPLE. These are among 1 currently registered trademark in the portfolio.
What is CIT eCapital, LLC's trademark registration success rate?
CIT eCapital, LLC has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.